What's in XIANG YANQUN's pipeline?

XIANG YANQUN has 5 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with XIANG YANQUN's portfolio?

Top competitors by shared drug class: Liaoning Cancer Hospital & Institute, Sun Yat-sen University, Tang-Du Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/xiang-yanqun.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

XIANG YANQUN — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

XIANG YANQUN pipeline: 0 marketed, 0 filed, 4 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
TPC combined with Tislelizumab	TPC combined with Tislelizumab	phase 3	Chemotherapy + PD-1 inhibitor combination	PD-1 (Tislelizumab component); TPC targets DNA/cell cycle	Oncology
Capecitabine/Placebo combined with toripalimab	Capecitabine/Placebo combined with toripalimab	phase 3	Fluoropyrimidine chemotherapy combined with PD-1 inhibitor	Thymidylate synthase (capecitabine) and PD-1 (toripalimab)	Oncology
GP Combined With Camrelizumab	GP Combined With Camrelizumab	phase 3	Chemotherapy + PD-L1 inhibitor combination	PD-L1 (camrelizumab component); DNA (gemcitabine/cisplatin component)	Oncology
GP combined with Tislelizumab	GP combined with Tislelizumab	phase 3	PD-1 inhibitor combined with chemotherapy	PD-1 (programmed death receptor 1)	Oncology

Therapeutic area mix

Oncology · 4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Liaoning Cancer Hospital & Institute · 1 shared drug class
Sun Yat-sen University · 1 shared drug class
Tang-Du Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for XIANG YANQUN:

Cite this brief

Drug Landscape (2026). XIANG YANQUN — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/xiang-yanqun. Accessed 2026-05-17.